中文

News Center

AACR 2026 | Doer Biologics Presents Preclinical Data on Bispecific Dual-Payload ADC

2026/04/16

Read more

Doer Biologics to Present Preclinical Results of DR319 Project at AACR 2026

2026/03/24

Read more

Approval of IND Application in China for Doer's DR30206 Injection Combined with Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

2026/03/03

Read more

Dr. Yongliang Fang on Endpoints News：Chinese biotech unveils first-in-class tri-agonist for high lipids

2025/12/31

Read more

Doer Biologics Announces First Patient Dosed in Phase Ib Clinical Trial of DR30206 for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

2025/11/21

Read more

Doer Biologics' Globally First-in-Class Drug DR10624 Phase II Clinical Data Presented in Opening Session at AHA 2025

2025/11/11

Read more

Blockbuster | Up to 75% Reduction in Triglycerides, Up to 67% Reduction in Liver Fat: Doer Bio's DR10624 Phase 2 Clinical Results Shine in Opening Session at AHA 2025

2025/11/11

Read more

Preview | To Kick Off the Conference!Huadong Medicine’s Subsidiary Doer Bio's DR10624 Phase 2 Results for Severe Hypertriglyceridemia Selected as AHA 2025 Late-Breaker and Featured as Opening Presentation

2025/09/16

Read more

Doer Biologics Completes First Patient Dosing in Phase II Clinical Trial of DR10624 for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) / Metabolic Dysfunction-Associated Steatohepatitis (MASH)

2025/04/22

Read more

Doer Biologics Announced Completes Enrollment of the Phase 2 Clinical Study of DR10624, reported by mainstream media

2025/03/12

Read more